Big Think2 weeks agoUX designLeadership essentials: "Inspire, motivate, and cultivate"Scribe Therapeutics, led by CEO Benjamin Oakes, aims to revolutionize genetic medicine through innovative genome editing technology. [ more ]
News Center3 months agoMedicineUnderstanding Inflammation in the Heart - News CenterInflammation in the heart can trigger immune responses even without immune cells, guiding myocarditis treatment. [ more ]
Big Think2 weeks agoUX designLeadership essentials: "Inspire, motivate, and cultivate"Scribe Therapeutics, led by CEO Benjamin Oakes, aims to revolutionize genetic medicine through innovative genome editing technology. [ more ]
News Center3 months agoMedicineUnderstanding Inflammation in the Heart - News CenterInflammation in the heart can trigger immune responses even without immune cells, guiding myocarditis treatment. [ more ]
www.fastcompany.com10 months agoHealthThe U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to followU.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia. The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year. The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level. [ more ]
www.fastcompany.com10 months agoHealthThe U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to followU.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia. The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year. The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level. [ more ]
www.fastcompany.com10 months agoHealthThe U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to followU.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia. The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year. The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level. [ more ]
www.fastcompany.com10 months agoHealthThe U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to followU.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia. The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year. The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level. [ more ]